Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
delayed orgasm.
Popular Articles

UT Gets Federal Stimulus Grant For Parkinson's Disease Research
The University of Texas Health Science Center at Houston has received a $412,500 federal stimulus grant for Parkinson"s disease research, the university announced today. It is the university"s first federal stimulus grant.
generic viagra
Boston Globe Examines U.S. Global Health Strategy
The Boston Globe examines the U.S. strategy towards global health aid. "President George W. Bush scored major advances in his administration"s worldwide campaign against AIDS," and "[t]he Obama administration believes it can leverage Bush"s successes into an assault against a much broader array of diseases that afflict poor countries," writes the Globe.
News of the day
How Superbugs Control Their Lethal Weapons
It appears that some superbugs have evolved to develop the ability to manipulate the immune system to everyone"s advantage.
Sexual Health

Dynavax Awarded Grant To Support Development Of TLR Inhibitors In Skin Diseases

Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax"s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008. "In addition to validating our proprietary technology, this new grant supports the preclinical studies for our TLR inhibitors, which represent a novel therapeutic approach for the treatment of inflammatory skin disorders," commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax Technologies. "Grant funding and partnerships with leading pharmaceutical companies help us advance the development of our TLR-based products targeting significant unmet medical needs." For more information about Dynavax"s TLR inhibitor program, visit here. Dynavax Technologies Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009